A new AI-driven blood test demonstrates high accuracy in detecting ovarian cancer. The test analyzes blood samples to identify biomarkers associated with the disease, offering a non-invasive diagnostic approach. Early detection tools like this could improve patient outcomes by enabling timely intervention.
AOA Dx raises **$17 million** to advance a **liquid biopsy test** for early ovarian cancer detection. The funding supports test development, leveraging blood-based analysis to identify biomarkers. The company targets improved diagnostic accuracy and earlier intervention for high-mortality ovarian cancer cases.
AOA Dx secures $17 million in Series B funding to advance its liquid biopsy diagnostic test for ovarian cancer. The company develops a platform enabling early detection through blood-based analysis. The investment supports test refinement and broader clinical application.
AOA DX develops a blood test detecting ovarian cancer risk through newly identified biomarkers in patient blood samples. The test aims to classify patients into high- or low-risk categories for early intervention. The company has secured seed funding to advance its diagnostic technology.
